Saitama clinic ordered to halt unauthorized stem cell ‘anti-aging’ therapy using umbilical cord blood – The Japan Times

SAITAMA The health ministry on Monday ordered a Saitama clinic to stop injecting stem cells of human umbilical cord blood into patients as an anti-aging treatment.

Saitama Medical Clinic in Tokorozawa, Saitama Prefecture, was found to have been engaged in such therapy without getting permission from the ministry. The regenerative medicine safety law mandates that all hospitals and clinics submit plans for stem cell therapy and get permission from the ministry beforehand.

The ministry conducted an on-site inspection of the clinic on Friday, based on tips from an outsider, and confirmed the clinic offered the unauthorized therapy, boasting that umbilical cord cell shots would boost health and help with anti-aging.

Several men and women are believed to have undergone treatment there. The ministry has asked the clinic to report the number of cases, any health damage and the kind of stem cells used and how they were obtained.

For clinics to receive approval for medical procedures using cells of others, they need to submit a detailed plan and have it screened by a panel of experts under the health ministry. The clinic had not submitted such a plan.

View original post here:
Saitama clinic ordered to halt unauthorized stem cell 'anti-aging' therapy using umbilical cord blood - The Japan Times

Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

New research provides further evidence of autologous hematopoietic stem cell transplantation as an effective treatment for multiple sclerosis, after finding the procedure halted disease progression for 5 years in almost half of patients.

Lead study author Dr. Paolo Muraro, of the Department of Medicine at Imperial College London in the United Kingdom, and colleagues recently reported their findings in JAMA Neurology.

The results come just a fortnight after another study revealed the success of a similar treatment in a small group of patients with relapsing-remitting multiple sclerosis (RRMS).

However, Dr. Muraro and team warn that further trials are needed to determine the efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT), after a small number of patients died within 100 days of treatment.

In AHSCT, a patient's own stem cells are harvested. The patient is then subject to high-dose chemotherapy to eliminate any diseased cells.

Next, the harvested stem cells are returned to the patient's bloodstream, with the aim of restarting normal blood cell production. In simple terms, AHSCT "resets" the immune system.

"We previously knew this treatment reboots or resets the immune system - and that it carried risks - but we didn't know how long the benefits lasted," notes Dr. Muraro.

For their study, the researchers assessed data from 25 treatment centers across 13 countries, identifying 281 patients with multiple sclerosis (MS) who underwent AHSCT between 1995-2006. Of these patients, 78 percent had a progressive form of MS.

Using the Expanded Disability Status Scale (EDSS), the team evaluated patients' progression-free survival at 5 years after treatment and any improvements in MS symptoms.

An EDSS score of zero represents no disability, seven represents the use of a wheelchair, while 10 represents death from MS. At the beginning of the study, patients had an average EDSS score of 6.5.

Overall, the researchers found that 46 percent of patients experienced no disease progression in the 5 years after treatment.

Patients with RRMS - characterized by inflammatory attacks, or "flare-ups," followed by periods of remission - had the best outcomes, with 73 percent experiencing no worsening of symptoms in the 5 years after AHSCT.

Additionally, patients experienced small improvements in MS symptoms after AHSCT. Patients with progressive MS saw their EDSS score rise by 0.14 a year after treatment, while patients with RRMS experienced a 0.76 increase in their EDSS score.

Patients with a younger age, few immunotherapies prior to AHSCT, and a lower EDSS score at study baseline also showed better outcomes with AHSCT.

While these findings show promise for the use of AHSCT for patients with MS, the team notes that there were eight deaths in the 100 days after AHSCT, which were thought to have been treatment related.

AHSCT involves aggressive chemotherapy, which can severely weaken the immune system and increase susceptibility to infection.

"In this study, which is the largest long-term follow-up study of this procedure, we've shown we can 'freeze' a patient's disease - and stop it from becoming worse, for up to 5 years.

However, we must take into account that the treatment carries a small risk of death, and this is a disease that is not immediately life-threatening."

Dr. Paolo Muraro

Dr. Muraro notes that, importantly, this study did not include a group of MS patients who did not receive treatment, further highlighting the need for more studies assessing the safety and efficacy of AHSCT.

"We urgently need more effective treatments for this devastating condition, and so a large randomized controlled trial of this treatment should be the next step," he adds.

Read about a study that links vitamin D level at birth to the risk of MS.

Here is the original post:
Multiple sclerosis: Stem cell transplantation may halt disease progression - Medical News Today

R3 Stem Cell Now Offering Regenerative Medicine Treatment in Oklahoma City – Satellite PR News (press release)

Submit the press release

Top Stem Cell Therapy in Oklahoma City (844) GET-STEM

Over 85% of patients at Venturis achieve excellent outcomes with regenerative medicine treatment for arthritis, tendonitis, back pain and more!

Oklahoma City, Oklahoma (PRWEB) February 20, 2017

R3 Stem Cell is now offering regenerative medicine treatment in Oklahoma City with a new Center of Excellence. R3 has partnered with Venturis Clinic, who offers stem cell and PRP therapy along with prolozone treatment by the Board Certified doctors. Call (844) GET-STEM for more information and scheduling.

Stem cell therapy is now mainstream, and helps individuals every day avoid the need for possibly risky surgery. Its helping athletes get back on the field faster, avoid joint replacement and finally achieve pain relief with chronic tendonitis conditions. The regenerative treatments are offered by a Board Certified provider in a contemporary setting.

The stem cell and PRP therapy in Oklahoma City are all outpatient with absolutely minimal risk. Unlike cortisone injections, these treatments actually repair and regenerate cartilage, muscle, bone, tendon, ligament and other damaged tissue.

Minimal down time is necessary after the stem cell therapy in Oklahoma City, which is the opposite of traditional surgery. The treatments contain stem cells, growth factors, concentrated platelets, cytokines and hyaluronic acid. The combination makes for an amazing regenerative environment once injected.

To receive cutting edge regenerative treatment, call Venturis Clinic in Oklahoma City which is now an R3 Stem Cell Center of Excellence at (844) GET-STEM. Also visit https://r3stemcell.com for more information.

Share article on social media or email:

Read the original:
R3 Stem Cell Now Offering Regenerative Medicine Treatment in Oklahoma City - Satellite PR News (press release)

Augmented adoptive cell transfer eradicates solid tumors [PreClinical] – 2 Minute Medicine

1. Combining tumor-specific T cells and pathogen-based immune stimulation, reenergized adoptive cell transfer (ReACT) targeted and eradicated tumor cells in mice.

2. ReACT led to increased migration of activated T cells to the tumors, a metric that correlated with decreased tumor size.

Evidence Rating Level: 2 (Good)

Study Rundown: Because cancer cells can evade being targeted by the bodys immune system, therapies have been developed to alter the tumors immune microenvironment. One therapy, adoptive cell transfer (ACT), involves engineering T cells to target cells that express tumor-associated antigens (TAAs). Although this therapy has potential, the tumor microenvironment causes inhibition of T cell function, preventing the therapys long-term efficacy. Another approach has been to use pathogens that express TAAs to stimulate the immune system. However, since some tumor cells have altered TAAs, they evade being targeted. In this study, these two approaches were combined into a therapy named ReACT: T cells were engineered to target a TAA as well as a bacterial antigen, and the cells were administered along with a bacterial adjuvant.

When treated with ReACT, a majority of mice with implanted melanoma cells experienced tumor eradication. An increased frequency of T cells in the tumor environment correlated with decreased tumor size. In addition, biomarker levels indicated effective T cell migration and activation. A polyclonal form of ReACT was also tested in a mouse model of melanoma; following tumor eradication in these mice, more tumor cells were introduced but failed to survive, demonstrating an immunological memory response induced by this therapy.

This study demonstrated a new approach for a safer and more efficacious cancer immunotherapy. Future studies will need to more closely mimic a clinical model and provide specific data describing the mechanism of T cell function in this therapy.

Click to read the study in PNAS

Relevant Reading: Cancer Immunotherapy: Strategies for Personalization and Combinatorial Approaches

In-Depth [animal study]: The researchers obtained CD8 T cells that expressed a T cell receptor (TCR) that recognizes a TAA specific to murine melanoma cells. These T cells were then engineered to express a TCR that recognizes the antigen ovalbumin (OVA). In mice with melanoma tumors, this treatment was only effective when the T cells were administered in conjunction with OVA conjugated to Listeria (LM-OVA), a model organism used for pathogen-based cancer vaccines. Seven out of 10 mice experienced complete tumor cell eradication (p<0.001). Neither the engineered T cells alone nor the LM-OVA alone was sufficient to produce significant tumor regression.

Next, the properties and functions of the ReACT T cells were analyzed. The CD8 T cells were present at a higher frequency in the ReACT-treated mice and this value negatively correlated to tumor size, with an r-value of -0.699. These T cells had an activated phenotype, with an increased expression of CD44 and other transcription factors as well as a decreased expression of inhibitory receptors such as CTLA-4. These T cells also had a high expression of CXCR3, a chemokine receptor involved in migration to tumor cells.

Finally, polyclonal ReACT was tested in mice with melanoma tumors. Tumor-specific CD8 T cells were generated by stimulating them with dendritic cells presenting a pool of TAAs; the cells were additionally engineered to express the OVA TCR, and administered to mice along with LM-OVA. Eleven out of 16 mice experienced complete tumor eradication. These mice were then reintroduced to the same melanoma cell line and were resistant to tumor relapse, demonstrating the establishment of an immunological memory response.

Image: PD

2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

2 Minute Medicines The Classics in Medicine: Summaries of the Landmark Trials is available now in paperback and e-book editions.

This text summarizes the key trials in:General Medicine and Chronic Disease, Cardiology, Critical and Emergent Care, Endocrinology, Gastroenterology, Hematology and Oncology, Imaging, Infectious Disease, Nephrology, Neurology, Pediatrics, Psychiatry, Pulmonology, and Surgery.

More here:
Augmented adoptive cell transfer eradicates solid tumors [PreClinical] - 2 Minute Medicine

R3 Stem Cell Now Offering Regenerative Medicine Treatment in Las Vegas and Henderson Nevada – PR Web (press release)

Top Stem Cell in Las Vegas and Henderson NV (844) GET-STEM

Las Vegas, Nevada (PRWEB) February 20, 2017

R3 Stem Cell is now offering regenerative medicine treatment in Las Vegas and Henderson Nevada. Treatments have helped many patients avoid surgery and improve their lives dramatically. R3 has partnered with Dynamic Stem Cell Therapy to offer treatment for all types of conditions. Call (844) GET-STEM for more information and scheduling.

Regenerative medicine therapy with stem cells has become mainstream, and the pioneers at Dynamic Stem Cell Therapy are experts. The conditions treated include arthritis, tendonitis, sports injuries, ligament injuries along with a host of systemic issues such as COPD, CHF, Lupus, Rheumatoid Arthritis, Crohns Disease, Diabetes and many more.

The Las Vegas stem cell center uses the patients adipose tissue, and concentrates the stem cells in a same day treatment. The treatment is offered either as an injection or an infusion, depending on the need.

The therapy works great for helping patients avoid the need for potentially risky surgery, such as joint replacement or tendonitis surgery. Not only does the procedure include stem cells, but also growth factors along with other healing agents.

Along with the adipose stem cell therapy, the Las Vegas stem cell doctors utilize platelet rich plasma therapy, known as PRP therapy for short. The combination of the two augment the capability of repair.

In addition to bone and joint conditions along with organ issues, Dynamic offers cosmetic procedures as well. This includes the Vampire facelift along with hair restoration that works great from platelet rich plasma therapy.

Over 85% of patients benefit from the regenerative medicine procedures. Call (844) GET-STEM for more information and scheduling with the top stem cell therapy in Las Vegas.

Share article on social media or email:

The rest is here:
R3 Stem Cell Now Offering Regenerative Medicine Treatment in Las Vegas and Henderson Nevada - PR Web (press release)

Cancer charity welcomes NHS u-turn on second stem cell … – The Guardian

Jeremy Hunt, the health secretary. Photograph: Dan Kitwood/Getty Images

Cancer campaigners have welcomed an NHS announcement that money may soon be available for a potentially lifesaving treatment it had previously refused to pay for.

The health service in England said on Sunday it was confident it would soon be able to announce funding for second stem cell treatments for blood cancer patients who have relapsed after an initial transfusion.

It came as the Anthony Nolan charity called on health secretary Jeremy Hunt to intervene on behalf of patients following a decision by the NHS last summer to refuse to pay for the second transfusions, saying they were more expensive and less effective than other drugs and treatments.

On Sunday night an NHS England spokeswoman: Last year medical experts ranked other new treatments as higher priority for new funding, but heading into the year beginning April 2017 we are confident the NHS will shortly be able to confirm funding for a further expansion of new treatments including second stem cell transplants.

Anthony Nolan said it was very welcome news.

Chief executive Henny Braund said: While it has tragically come too late for patients who have been denied this lifesaving treatment in the past year, this decision by NHS England will ultimately mean in future, patients and families can be reassured that they will now be able to receive the appropriate treatment should their blood cancer return.

In a poll of 1,700 people carried out by Populus on behalf of the charity, 66% of respondents said patients who relapsed after their first treatment should be given a second round, and almost half said it was unacceptable for friends or family to have to foot the bill. Almost six in 10 said the government was not doing a good enough job of making sure the NHS had the money to fund the treatments people needed.

Before the announcement, Lisa Hepburn, whose husband Gavin died last year after two attempts to get an individual request for a second stem cell treatment were rejected, said: Theres no explanation from the NHS; nothing from the heart. I feel for people who are in the situation of having to raise the money themselves. I cant believe the government can put a price on a persons life thats what they are doing.

Last week a group of charities wrote to Theresa May urging her to stop the NHS rationing treatment for people with serious illnesses and to find more money for care in next months budget.

Original post:
Cancer charity welcomes NHS u-turn on second stem cell ... - The Guardian

Stem Cell therapy is future of anti-ageing – Bangalore Mirror

Chronological aging shows the natural life cycle of the cells as opposed to cells that have been unnaturally replicated multiple times or otherwise manipulated in a lab.

In order to preserve the cells in their natural state, Penn researchers developed a system to collect and store them without manipulating them, making them available for this study. They found stem cells collected directly from human fat -- called adipose-derived stem cells (ASCs) -- can make more proteins than originally thought. This gives them the ability to replicate and maintain their stability, a finding that held true in cells collected from patients of all ages.

Our study shows these cells are very robust, even when they are collected from older patients, said Ivona Percec, MD, director of Basic Science Research in the Center for Human Appearance and the studys lead author. It also shows these cells can be potentially used safely in the future, because they require minimal manipulation and maintenance.

Stem cells are currently used in a variety of anti-aging treatments and are commonly collected from a variety of tissues. But Percecs team specifically found ASCs to be more stable than other cells, a finding that can potentially open the door to new therapies for the prevention and treatment of aging-related diseases.

Unlike other adult human stem cells, the rate at which these ASCs multiply stays consistent with age, Percec said.

Continued here:
Stem Cell therapy is future of anti-ageing - Bangalore Mirror

Why the United States is no longer turning up its nose at Caribbean medical schools – STAT

M

ORENO VALLEY, Calif. Its easy to dismiss the for-profit medical schools that dot many a Caribbean island as scams, set up to woo unqualified students who rack up huge debts, drop out in staggering numbers, and if they make it to graduation end up with an all but worthless degree. Thats been the rap against them for years.

But the schools are determined to change that image. Many are quietly churning out doctors who are eager to work in poor, rural, and underserved communities. Their graduates embrace primary care and family practice, in part because theyre often shut out of training slots for more lucrative specialties.

And they just might help solve an urgent physician shortage in California and beyond.

The deans of two of the Caribbeans medical schools Ross University School of Medicine in Dominica and American University of the Caribbean in St. Maarten are on an aggressive campaign to improve their image. Theyve published a series of editorials and letterswith titles like Why malign overseas medical students? and hired public relations giant Edelman to make the case that their humble, hard-working, and compassionate students may be precisely the kinds of physicians America needs most.

Our students have persevered. They havent had all the opportunities in life and they still want to help people, said Dr. Heidi Chumley, dean of American University of the Caribbean School of Medicine. Absolutely we want to get our story out.

That story is unfolding on the ground in places like Moreno Valley, a city ofabout 200,000 in Californias Inland Empire, a former agricultural region just east of Los Angeles that grew explosively in the 80s but has since fallen on harder times.

Here, the Riverside University Health System Medical Centerrises from a stretch of largely undeveloped land once slated for luxury housing developments. The health system acts as the countys public safety net for an ethnically diverse, mostly low-income population including patients like retired carpenter Jos Luis Garcia.

On a recent clinic visit, Garcia, 69, came in to follow up on a urinary tract infection and his high blood sugar. He saw Dr. Moazzum Bajwa, 30, a second-year resident and graduate of Ross.

In a crisp white coat and bow tie, Bajwa entered the examining room and pulled up a low stool. Sitting eye to eye with Garcia, he spoke in a steady stream of fluent Spanish. The visit lasted nearly an hour.

In an attempt to keep his patient off insulin, Bajwa had asked Garcia to improve his diet and track blood sugar levels after meals. Nmeros fantsticos!, Bajwa exclaimed, looking at the folded sheet of carefully written numbers Garcia had brought to show him.

This is a very great doctor. Normally, I dont feel important.

Jos Luis Garcia, patient

Bajwa, a former middle school science teacher, then spent 10minutes drawing a careful diagram complete with neurons, intestinal walls, and red blood cells, orclulas rojas to explain to a rapt Garcia exactly why certain foods raised his blood sugar. He then examined Garcia noting he had a harmless but interesting muscle wall abnormality and checked his medical records. Was there a colonoscopy report on file? Retinal photos?

As the visit was ending, Bajwa asked Garcia about stress. Garcia said his wife had recently had surgery for glioblastoma multiforme, one of the most malignant of brain tumors. Wow, Bajwa said quietly as he quickly scanned the medical summary Garcia handed him. Wow. He sat down again on his low stool.

Lo siento mucho, seor, Bajwa said, clearly moved.

Then he gave Garcia a hug.

This is a very great doctor, Garcia said later, through a translator. Normally, I dont feel important.

Bajwa, an American citizen raised inMichigan and North Carolina, is the grandson of Pakistani Nobel physics laureate Abdus Salam and holds two advanced degrees, one in neuroanatomy and one in public health. But he couldnt get into an American medical school. So he attended Ross University in Dominica.

It was the only school that gave me an opportunity, he said.

There are some 70 medical schools throughout the Caribbean, most of them established in recent decades and run by for-profit businesses thatcater to Americans.

These so-called second chance schools accept students with poorer grades and lower MCAT scores, or sometimes no MCAT score at all. Compared to Americanmedical schools, their tuition and dropout rates are higher and their class sizes large: Ross enrolls more than 900 students per year.

Graduates can practice medicine in the United States after passing their Americanmedical licensing exams and completing a residency. But the schools have come under fire for generating a stream of students who dont end up as physicians, but do end up with crushing medical school debt because they flunk out or dont win residency spots after graduating.

Heartbreaking stories abound: One graduate of St. Georges University School of Medicine took a poor-paying job drawing blood to help pay off $400,000 in medical school loans. Another graduate of AUC entered nursing school after failing to get a residency.

Are Caribbean medical schools promising something they cannot fulfill? asked Dr. Glenn Tung, an associate dean at Brown Universitys Warren Alpert Medical School who has studied the schools. What Im concerned about is the cost to the students who dont make it and the cost to the American taxpayer when loans arent repaid.

Illinois Senator Richard Durbin, also concerned, has repeatedly introducedbipartisan legislation to strip the schools of Title IV federal funding for student loans. Three Caribbean medical schools Ross, AUC and St. Georges took in $450 million federal funding via student loans in 2012, Durbin said.

These for-profit Caribbean medical schools need to be accountable to their students and to U.S. taxpayers, he said in a statement.

Dean Chumley and Dr. Joseph Flaherty, the dean of Ross, take strong exception to such criticism.

They allow that many for-profit medical schools which have proliferated in the past few decadesbecause they are proven money makers arent doing a good job training and developing students. But they argue that AUC and Ross, two of the oldest Caribbean schools both owned by for-profit educational juggernaut DeVry Inc. are creating successful doctors.

They say they are also giving a shot to students with humble backgrounds, often minorities, who cant get near American medical schools that focus so heavily on test scores and grades.

Obviously brains help, but judgement, empathy, intuition, thats all part of it, Flaherty said. Our students are gung-ho. They want to practice medicine. Thats their dream.

Just 54 percent of American medical graduates who trained overseas are matched with a residency program for further training in their first year of eligibility. Thats an abysmal record, compared to the 94 percent of graduates of US schools who get residencies. But Ross and AUC say they have a match rates higher than 86 percent. And they say a vast majority of students pass their step 1 licensing exams on the first try.

Obviously brains help, but judgement, empathy, intuition, thats all part of it Our students are gung-ho.

Dr. Joseph Flaherty, dean of a Caribbean medical school

(Critics say the schools manipulate the statistics by dismissing weak students shortly before they are allowed to take the exams. Chumley said the schools do weed out poor students early on to prevent their accumulating debt, but in no way encourage poor students to stay for five semesters and then prevent them from taking the exam. I think thats ethically wrong, she said.)

The schools are also controversial because of their practice of buying their way into hospitals to train students. In 2012, Ross inked a contract beating out rival St. Georges University School of Medicine of Grenada to pay $35 million over a decadeto the cash strapped Kern Medical Center in Bakersfield in exchange for the lions share of the hospitals roughly 100 rotation spots for third-year medical students.

Some critics fear such deals will squeeze American-trained students out of rotations; disputes have flared in New York, where St. George paid $100 million for rotation spots, and in Texas, where lawmakers attempted to entirely ban Caribbean students from training in the state.

But Flaherty, Rosss dean, says the such deals are a win-win. A struggling hospital gets funds. His school, which has no teaching hospital, gets a place to train students. And he gets to show skeptical doctors how good his students really are.

The doctors get to know our students and say, These guys are good, he said. Our students get there early. They stay late and do extra work. They value any opportunity.

And they seize those opportunities where they can find them.

While their numbers are up, its still harder for international medical grads known as IMGs to get residency positions. Theyveheard all the jokes about studying anatomy on the beach with Mai Tais in hand. But when it comes to residency positions, they are deadly serious. For there is no practicing medicine without one.

You have to apply very widely. Theres always a stigma that IMGs dont get as good an education. said Rina Seerke-Teper, 31, a second-year resident who has wanted to be a doctor since she was six, graduated from the University of California at Berkeley and worked in stem cell research before attending AUC.

Many Caribbean graduates dont even apply to residency programs that are filled only with American trained students. Instead, they look for IMG friendly programs like the family practice residency here, run in a busy clinic housed within the county hospital. The program is highly competitive receiving about 800 applications for 12 positions each year and of the three dozen current residents, 29 studied in a medical school outside the US.

Competition for the coveted slots is likely to grow even more as California, which just got one newmedical schools and is slated to soon add another, starts spitting out more locally trained grads.

More doctors are desperately needed: California will need an estimated 8,000 additional primary care doctors by 2030. The United States as a whole is projected to need some 30,000 additional primary care physicians in coming decades.

Dr. Michelle Quiogue works in one of the areas hit hardest by the shortage rural Kern County. A graduate of a prestigious medical school at Brown University Quiogue says shes worked alongside many foreign-trained doctors and would never know what college they graduated from.

Inher mind, the problem is not a lack of medical students but a lack of residency programs to train them. The governor has proposedcutting $100 million for primary care residency training, and her organization, the California Academy of Family Physicians, is scrambling to get it replaced.

Medical school hasnt changed much in a century. Here are 5 ways to fix that

Those who do win residency spots say it seems to matter less and less where they went to school as they climb up the medical training ladder. And it seems to matter not at all in clinics where patients are grateful for any medical care they receive.

I have never heard a patient ask where a physician is trained, said Carly Barruga, a third year medical student at nearby Loma Linda University who said she is getting excellent training in her rotation here from Caribbean-trained doctors like Dr. Tavinder Singh.

Singh, 30, is chief resident here and also a graduate of Ross. While he traces his interest in medicine to the open heart surgery his grandmother had when he was a boy, Singh didnt apply to American medical schools because his MCATs werent as strong as they should have been. He didnt want to wait a year to retake them.

I had the goal in mind I was going to be a doctor, said Singh, a California native. Nothing was going to stop me. Hes loved his residency, especially the chance to work in needy communities where medical zebras unlikely and rare diagnoses can be common. You see chronic disease that have never been treated, he said. You see rare diseases like Zika.

While Singh was once the one begging for a chance, the tables have turned. In a state hungry for family practice physicians, hes now fielding numerous job offers.

Bajwas future is bright as well.

For now, though, hes just happy to be practicing medicine, thrilled to be delivering babies and focusing on preventative care. He loves helping patients like Wendy Ocampo, a 19-year-old with limb girdle muscular dystrophy. During an appointment this month, Ocampo came in to see Bajwa with respiratory symptoms.

New medical schools aim to fix Americas broken health care system

It was supposed to be a quick visit, but he ended up spending a half hour with her once he discovered bureaucratic hurdles had left her waiting seven months for the wheelchair she needs for her job and college. (Bajwa credits his clinic staff and nurses for working through lunch and juggling his schedule so he can offer longer visits.) Ocampo also hasnt been able to get the physical therapy she needs for her ankle.

It burns me up that these things are falling through the cracks, said Bajwa, after taking a few minutes to compliment Ocampos impressive new shoes and ask if she was growing out her hair.

Though sick, Ocampo beamed. Honestly, hes great, she said. He calls me to check on me. I have, like, 30 doctors and none of them have ever done that.

Correction: A previous version of this story misstated the population for Moreno Valley and the status of a proposed funding cut for residency training.

Usha Lee McFarling can be reached at usha.mcfarling@gmail.com Follow Usha Lee on Twitter @ushamcfarling

See the original post:
Why the United States is no longer turning up its nose at Caribbean medical schools - STAT

How researchers in Vail are pursuing breakthroughs to help injuries heal faster and some day slow down the way … – The Denver Post

VAIL Hallways at the world-famous Steadman Clinic are lined with framed, autographed jerseys of star athletes who have had surgery here, including John Elway, Mario Lemieux and Alex Rodriguez.

The clinic and its associated Steadman Philippon Research Institute (SPRI) attract world-class talent from all fields including U2 drummer Larry Mullen Jr., who joined the institutes board after he was a patient here but perhaps its top recruit was a renowned scientist researching ways to help injuries heal faster and slow down the way our bodies age.

Were trying to develop the iPhone 9 of medicine, said Dr. Johnny Huard, chief scientific officer and director of the institutes Center for Regenerative Sports Medicine. Your iPhone 6 and 7 are great, its doing everything you want, but youre looking on the web at what the iPhone 8s going to do. We want to have surgeons here doing surgery on our best football, hockey, basketball players, and instead of losing a year to heal, can we heal them in six months? Three months? Would that be great?

Joe Amon, The Denver Post

The field is called biologics, and its transforming orthopedics by using cells that heal produced in the patients body in concentrated injections that can hasten tissue repair directly at the site of the injury. Huard is leading cutting-edge research into stem cells and platelet-rich plasma (PRP) therapy that he believes will some day delay age-related diseases and cut the recovery time from serious injuries, such as to the knee, in half.

Stem cells are undifferentiated cells that can become specialized cells muscle, bone, cartilage to help repair tissue. Platelets carry proteins that help in the healing process. The breakthroughs Huard and his colleagues are pursuing hold exciting promise for weekend warriors as well as for star athletes.

I dont think we can reverse aging, but I think we can age better and recover from injury better, said Dr. Marc Philippon, managing partner of the Steadman Clinic and co-chairman of the research institute. As a surgeon my biggest challenge is, if I cut on you theres always that healing phase. We want to recover faster. But the most important thing is prevention of injury. If your cells are aging better, youll have less injury. The way I look at it, thats going to put us out of business, but thats OK. Its a good way to go out of business.

A world-class scientist, Huard discovered muscle-derived stem cells in 1998. Before joining SPRI two years ago he was the director of the Stem Cell Research Center at the University of Pittsburgh.Researchers here believe injections of stem cells and PRP can help delay or prevent the need for joint replacements, and at the adjacent clinic they can test their theories in clinical trials. They have shown in animal studies that young stem cells can rejuvenate old stem cells.

To that end Huard advocates passionately that when a child is born, stem cells from the umbilical cord should be harvested and frozen at minus-80 degrees Fahrenheit. As bodies age, stem cells diminish in number and vitality, but they can be preserved in suspended animation while frozen. Those cells later can be thawed and reintroduced into the body as younger and more robust stem cells than the ones that have aged in the patient, performing like a fountain of youth.

Thats the best gift you can give to that baby, said Huard, a French Canadian with a playful wit. Its the best gift you can give to that mother, too, because that (umbilical cord) is part of her, too. Its not only part of the baby. Can you believe the impact of that?

Stem cells, aging and exercise

Because stem cells can develop into every cell type in the body, researchers believe they can be used to hasten repair of nerves, bone and muscle. Bone marrow transplants are the most common form of stem cell therapy currently in use, but stem cells may be useful in fighting neurodegenerative diseases and other conditions.

We can use them to repair bone, cartilage, the heart, the bladder, Huard said. We have clinical trials now ongoing for bladder and the heart.

Imagine a Broncos running back blowing out his anterior cruciate ligament in training camp but being able to return to the field during the regular season. Huardforesees that day, as well as a time when patients whose stem cells were harvested and stored at birth will be able to have them injected into their knees decades later after ACL repair, for example, which theoretically could allow the person to recover much faster.

If I harvest stem cells from your muscle today, lets say I find 100 stem cells, but if I do the same thing 30 years ago I may have gotten 10,000, Huard said. Not only that, but the 100 stem cells you have are tired. They have been dividing and trying to repair your muscle.

When one of Huards children was born 17 years ago and it came time for Huard to cut the umbilical cord, he asked the nurse what they were going to do with it.

My wife said, Can you stop being a scientist and be my husband for a minute here? Huard tells the story with amusement, but he is passionate that umbilical cord stem cells should be saved.

I tell people, No more flowers, just freeze the stem cells from that newborn, Huard said. Thats the best gift you can give to that kid.

In the meantime, Huard believes exercise remains the best anti-aging mitigation we have. Beyond the benefits already well known, he is convinced exercise increases the production of stem cells and delays the aging process.Researchers found that mice that run on treadmills heal significantly faster than sedentary mice. Mice who exercised also had a better survival rate after being injected with cancer cells than those that were sedentary.

Huardbelieves exercise helps the brain as well as the heart in ways that might not be fully understood but might have implications for the prevention or delay of dementia and Alzheimers.

Stem cells come from blood vessels, Huard said. What can we do to increase the number of blood vessels? If we can do that, then we can probably improve tissue repair. If you exercise, you increase the number of blood vessels in your tissues.

Platelet-rich plasma therapy

PRP therapy is already in widespread use, not just in elite athletes but in recreational athletes as well. Sometimes it works well, and sometimes it doesnt work at all. Huard is trying to find out why.

Platelets in the blood carry proteins called growth factors that help the body repair injured tissue. In PRP therapy, a patients blood is removed and spun in an centrifuge or filtered to separate platelets. Then the platelet-rich plasma is injected into the site of an injury with hopes of speeding the healing process.

When you injure something, you bleed, Philippon said in his office with a view of Vails ski trails. Some of the first elements going there are your platelets, and theres a reason for that. Platelets have the growth factors, also what we call the chemotactic factors, to attract whats needed (to heal).

Philippon has used PRP to hasten healing of hip tendons in football players, for example.

What we found was that those I injected with PRP early recovered faster, Philippon said. We have that data here. We know, for a tendon injury, PRP is a great therapy.

Huard had elbow surgery last year after snapping a tendon off the bone in a ski accident I like to go fast, he said with a grin and Steadman surgeon Peter Millett asked Huard if he wanted a PRP injection in hopes of hastening recovery.

I said, Of course! You know what? I never wore a sling, Huard said. The week after, I was running. Three weeks after, I was back skiing.

But did the PRP help?

I dont know, Huard said.

So Huard is studying the success rate of PRP therapy in patients who receive it after surgery at the Steadman Clinic. When Philippon uses PRP on a patient, for example, he will set aside a fraction of that PRP and give it to Huard to analyze in the lab. Huard will catalog the different growth factors in each sample and then wait to see how the patients respond.

After this Im going to go back to Marc and say: Which patient worked? Which one was your best patient? Huard said. If he tells me patient No. 24 and 32 and 48, Im going to go back and try to see what those three patients PRP had in common in terms of growth factors.

Then Huard will be able to better advise surgeons before using PRP.

Lets say we find when IGF1 (insulin growth factor one) is high in your blood, PRP always works, Huard said. You know what Im going to give to those surgeons? Im going to say, Before you give PRP, take a blood draw, we go in the lab, test for IGF1, and if IGF1 is high, 95 percent chance PRP is going to help. But another patient, if IGF1 is not high, Based on our tests, I dont think PRP is going to help.

Another thing we found in PRP, it is a mixed bag. You have good things in PRP but you have bad things, too. So were doing science where Im going to take PRP, Im going to take out the bad guys.

As with stem cells, Huard foresees a day when a young patients PRP can be frozen and used decades later to delay aging, administered in conjunction with stem cell injections to work in synergy.

I think the two can be combined somehow, Huard said. They are different, but the stem-cell therapy and the PRP somehow can be together. If I have your PRP from 20 years ago and I have your stem cells from 20 years ago, I can make a very nice mixture, inject this into you. Sometimes adding one thing to another, biologically, it equals not two but three.

Having his laboratory in the same building as the Steadman Clinic, which has eight surgeons on staff, is a boon for Huard in his research. He takes ideas to them and vice versa.

I dont do science just to do science, he said. I do science to improve quality of life, and I think I can make a major contribution in the field. If you delay aging by 10 years, you delay all those age-related disorders by 10 years. The implications for health care is amazing.

Biologics: Using tools produced by a patients body such as stem cells and platelet-rich plasma (PRP) to help the patient heal faster and better.

Regenerative medicine: This and tissue engineering are promising treatment approaches that can enhance or promote musculoskeletal tissue healing and regeneration following surgery or injection therapy. Biological treatments such as growth factor supplementation, PRP and bone marrow concentrate have been shown to improve patient function and quality of life.

Platelet-rich plasma: A biologic treatment that is produced by concentrating the patients own blood to yield a high platelet count. Platelets are important blood components that secrete hundreds to thousands of biological factors that initiate musculoskeletal tissue healing and regeneration.

Stem cells: Stem cells have the ability to transform into specific musculoskeletal tissue cells. These types of cells also secrete biological factors that initiate musculoskeletal tissue healing and regeneration. There are several forms of stem cells, such as muscle-derived stem cells, bone marrow-derived stem cells, adipose-derived stem cells and others.

John Meyer, The Denver Post

View original post here:
How researchers in Vail are pursuing breakthroughs to help injuries heal faster and some day slow down the way ... - The Denver Post

Types of Stem Cell Transplants for Cancer Treatment …

In a typical stem cell transplant for cancer very high doses of chemo are used, sometimes along with radiation therapy, to try to kill all the cancer cells. This treatment also kills the stem cells in the bone marrow. Soon after treatment, stem cells are given to replace those that were destroyed. These stem cells are given into a vein, much like a blood transfusion. Over time they settle in the bone marrow and begin to grow and make healthy blood cells. This process is called engraftment.

There are 2 main types of transplants. They are named based on who gives the stem cells.

In this type of transplant, your own stem cells are removed, or harvested, from your blood before you get treatment that destroys them. Your stem cells are removed from either your bone marrow or your blood, and then frozen. (You can learn more about this process at Whats It Like to Donate Stem Cells?) After you get high doses of chemo and/or radiation, the stem cells are thawed and given back to you.

One advantage of autologous stem cell transplant is that youre getting your own cells back. You dont have to worry about the new stem cells (called the engrafted cells or the graft) attacking your body (graft-versus-host disease) or about getting a new infection from another person. But there can still be graft failure, which means the cells dont go into the bone marrow and make blood cells like they should. Also, autologous transplants cant produce the graft-versus-cancer effect.

This kind of transplant is mainly used to treat certain leukemias, lymphomas, and multiple myeloma. Its sometimes used for other cancers, like testicular cancer and neuroblastoma, and certain cancers in children. Doctors are looking at how autologous transplants might be used to treat other diseases, too, like systemic sclerosis, multiple sclerosis (MS), Crohn's disease, and systemic lupus erythematosis (lupus).

A possible disadvantage of an autologous transplant is that cancer cells may be collected along with the stem cells and then later put back into your body. Another disadvantage is that your immune system is the same as it was before your transplant. This means the cancer cells were able to escape attack from your immune system before, and may be able to do so again.

To help prevent this, some centers treat the stem cells before theyre given back to the patient to try to kill any remaining cancer cells. This may be called purging. It isnt clear that this really helps, as it has not yet been proven to reduce the risk of cancer coming back. A possible downside of purging is that some normal stem cells can be lost during this process. This may cause your body to take longer to start making normal blood cells, and you might have very low and unsafe levels of white blood cells or platelets for a longer time. This could increase the risk of infections or bleeding problems.

Another treatment to help kill cancer cells that might be in the returned stem cells involves giving anti-cancer drugs after transplant. The stem cells are not treated. After transplant, the patient gets anti-cancer drugs to get rid of any cancer cells that may be in the body. This is called in vivo purging. For instance, rituximab (Rituxan), a monoclonal antibody drug, may be used this way in certain lymphomas and leukemias; lenalidomide (Revlimid) may be used for multiple myeloma. The need to remove cancer cells from transplanted stem cells or transplant patients and the best way to do it is being researched.

Doing 2 autologous transplants in a row is known as a tandem transplant or a double autologous transplant. In this type of transplant, the patient gets 2 courses of high-dose chemo, each followed by a transplant of their own stem cells. All of the stem cells needed are collected before the first high-dose chemo treatment, and half of them are used for each transplant. Usually, the 2 courses of chemo are given within 6 months. The second one is given after the patient recovers from the first one.

Tandem transplants are most often used to treat multiple myeloma and advanced testicular cancer. But doctors dont always agree that these are really better than a single transplant for certain cancers. Because this involves 2 transplants, the risk of serious outcomes is higher than for a single transplant. Tandem transplants are still being studied to find out when they might be best used.

Sometimes an autologous transplant followed by an allogeneic transplant might also be called a tandem transplant. (See Mini-transplants below.)

Allogeneic stem cell transplants use cells from a donor. In the most common type of allogeneic transplant, the stem cells come from a donor whose tissue type closely matches the patients. (This is discussed later in Matching patients and donors.) The best donor is a close family member, usually a brother or sister. If you dont have a good match in your family, a donor might be found in the general public through a national registry. This is sometimes called a MUD (matched unrelated donor) transplant. Transplants with a MUD are usually riskier than those with a relative who is a good match.

Blood taken from the placenta and umbilical cord of newborns is a newer source of stem cells for allogeneic transplant. Called cord blood, this small volume of blood has a high number of stem cells that tend to multiply quickly. But there are often not enough stem cells in a unit of cord blood for large adults, so most cord blood transplants done so far have been in children and smaller adults. Researchers are now looking for ways to use cord blood for transplants in larger adults. One approach is to find ways to increase the numbers of these cells in the lab before the transplant. Another approach is the use of the cord blood from 2 infants for one adult transplant, called a dual-cord-blood transplant. A third way cord blood is being used is in a mini-transplant (see below). Other strategies to better use cord blood transplants are being actively studied.

Pros of allogeneic stem cell transplant: The donor stem cells make their own immune cells, which could help kill any cancer cells that remain after high-dose treatment. This is called the graft-versus-cancer effect. Other advantages are that the donor can often be asked to donate more stem cells or even white blood cells if needed, and stem cells from healthy donors are free of cancer cells.

Cons to allogeneic stem cell transplants: The transplant, or graft, might not take that is, the transplanted donor stem cells could die or be destroyed by the patients body before settling in the bone marrow. Another risk is that the immune cells from the donor may not just attack the cancer cells they could attack healthy cells in the patients body. This is called graft-versus-host disease. There is also a very small risk of certain infections from the donor cells, even though donors are tested before they donate. A higher risk comes from infections you had previously, and which your immune system has had under control. These infections may surface after allogeneic transplant because your immune system is held in check (suppressed) by medicines called immunosuppressive drugs. Such infections can cause serious problems and even death.

Allogeneic transplant is most often used to treat certain types of leukemia, lymphomas, multiple myeloma, myelodysplastic syndrome, and other bone marrow disorders such as aplastic anemia.

For some people, age or certain health conditions make it more risky to wipe out all of their bone marrow before a transplant. For those people, doctors can use a type of allogeneic transplant thats sometimes called a mini-transplant. Your doctor might refer to it as a non-myeloablative transplant or mention reduced-intensity conditioning (RIC). Patients getting a mini transplant get less chemo and/or radiation than if they were getting a standard transplant. The goal is to kill some of the cancer cells (which will also kill some of the bone marrow), and suppress the immune system just enough to allow donor stem cells to settle in the bone marrow.

Unlike the standard allogeneic transplant, cells from both the donor and the patient exist together in the patients body for some time after a mini-transplant. But slowly, over the course of months, the donor cells take over the bone marrow and replace the patients own bone marrow cells. These new cells can then develop an immune response to the cancer and help kill off the patients cancer cells the graft-versus-cancer effect.

One advantage of a mini-transplant is that it uses lower doses of chemo and/or radiation. And because the stem cells arent all killed, blood cell counts dont drop as low while waiting for the new stem cells to start making normal blood cells. This makes it especially useful for older patients and those with other health problems. Rarely, it may be used in patients who have already had a transplant.

Mini-transplants treat some diseases better than others. They may not work well for patients with a lot of cancer in their body or people with fast-growing cancers. Also, although side effects from chemo and radiation may be less than those from a standard allogeneic transplant, the risk of graft-versus-host disease is the same.

This procedure has only been used since the late 1990s and long-term patient outcomes are not yet clear. There are lower risks of some complications, but the cancer may be more likely to come back. Ways to improve outcomes are still being studied.

Studies have looked at using an allogeneic mini-transplant after an autologous transplant. This is another type of tandem transplant being tested in certain types of cancer, such as multiple myeloma and some types of lymphoma. The autologous transplant can help decrease the amount of cancer present so that the lower doses of chemo given before the mini-transplant can work better. And the recipient still gets the benefit of the graft-versus-cancer effect of the allogeneic transplant.

This is a special kind of allogeneic transplant that can only be used when the patient has an identical sibling (twin or triplet) someone who has the exact same tissue type. An advantage of syngeneic stem cell transplant is that graft-versus-host disease will not be a problem. Also, there are no cancer cells in the transplanted stem cells, as there might be in an autologous transplant.

A disadvantage is that because the new immune system is so much like the recipients immune system, theres no graft-versus-cancer effect. Every effort must be made to destroy all the cancer cells before the transplant is done to help keep the cancer from coming back.

Some centers are doing half-match (haploidentical) transplants for people who dont have closely matching family members. This technique is most often used in children, usually with a parent as the donor, though a child can also donate to a parent. Half of the HLA factors will match perfectly, and the other half typically dont match at all, so the procedure requires a special way to get rid of a certain white blood cells that can cause graft-versus-host disease. Its still rarely done, but its being studied in a few centers in the US. Researchers are continuing to learn new ways to make haploidentical transplants more successful.

Depending on the type of transplant thats done, there are 3 possible sources of stem cells to use for transplants:

Bone marrow is the spongy liquid tissue in the center of some bones. It has a rich supply of stem cells, and its main job is to make blood cells that circulate in your body. The bones of the pelvis (hip) have the most marrow and contain large numbers of stem cells. For this reason, cells from the pelvic bone are used most often for a bone marrow transplant. Enough marrow must be removed to collect a large number of healthy stem cells.

The bone marrow is harvested (removed) while the donor is under general anesthesia (drugs are used to put the patient into a deep sleep so they dont feel pain). A large needle is put through the skin on the lower back and into the back of the hip bone. The thick liquid marrow is pulled out through the needle. This is repeated until enough marrow has been taken out. (For more on this, see Whats It Like to Donate Stem Cells?)

The harvested marrow is filtered, stored in a special solution in bags, and then frozen. When the marrow is to be used, its thawed and then put into the patients blood through a vein, just like a blood transfusion. The stem cells travel to the bone marrow, where they engraft or take and start to make blood cells. Signs of the new blood cells usually can be measured in the patients blood tests in about 2 to 4 weeks.

Normally, not many stem cells are found in the blood. But giving shots of hormone-like substances called growth factors to stem cell donors a few days before the harvest causes their stem cells to grow faster and move from the bone marrow into the blood.

For a peripheral blood stem cell transplant, the stem cells are taken from blood. A special thin flexible tube (called a catheter) is put into a large vein in the donor and attached to tubing that carries the blood to a special machine. The machine separates the stem cells from the rest of the blood, which is returned to the donor during the same procedure. This takes several hours, and may need to be repeated for a few days to get enough stem cells. The stem cells are filtered, stored in bags, and frozen until the patient is ready for them. (For more on this, see Whats It Like to Donate Stem Cells?)

When theyre given to the patient, the stem cells are put into a vein, much like a blood transfusion. The stem cells travel to the bone marrow, engraft, and then start making new, normal blood cells. The new cells are usually found in the patients blood in about 10 to 20 days.

A large number of stem cells are normally found in the blood of newborn babies. After birth, the blood thats left behind in the placenta and umbilical cord (known as cord blood) can be taken and stored for later use in a stem cell transplant. The cord blood is frozen until needed. A cord blood transplant uses blood that normally is thrown out after a baby is born. More information on donating cord blood can be found in Whats It Like to Donate Stem Cells?

A possible drawback of cord blood is the smaller number of stem cells in it. But this is partly balanced by the fact that each cord blood stem cell can form more blood cells than a stem cell from adult bone marrow. Still, cord blood transplants can take longer to take hold and start working. Cord blood is given into the patients blood just like a blood transfusion.

It is very important that the donor and recipient are a close tissue match to avoid graft rejection. Graft rejection happens when the recipients immune system recognizes the donor cells as foreign and tries to destroy them as it would a bacteria or virus. Graft rejection can lead to graft failure, but its rare when the donor and recipient are well matched.

A more common problem is that when the donor stem cells make their own immune cells, the new cells may see the patients cells as foreign and attack their new home. This is called graft-versus-host disease. (See Stem Cell Transplant Side Effects for more on this). The new, grafted stem cells attack the body of the person who got the transplant. This is another reason its so important to find the closest match possible.

Many factors play a role in how the immune system knows the difference between self and non-self, but the most important for transplants is the human leukocyte antigen (HLA) system. Human leukocyte antigens are proteins found on the surface of most cells. They make up a persons tissue type, which is different from a persons blood type.

Each person has a number of pairs of HLA antigens. We inherit them from both of our parents and, in turn, and pass them on to our children. Doctors try to match these antigens when finding a donor for a person getting a stem cell transplant.

How well the donors and recipients HLA tissue types match plays a large part in whether the transplant will work. A match is best when all 6 of the known major HLA antigens are the same a 6 out of 6 match. People with these matches have a lower chance of graft-versus-host disease, graft rejection, having a weak immune system, and getting serious infections. For bone marrow and peripheral blood stem cell transplants, sometimes a donor with a single mismatched antigen is used a 5 out of 6 match. For cord blood transplants a perfect HLA match doesnt seem to be as important, and even a sample with a couple of mismatched antigens may be OK.

Doctors keep learning more about better ways to match donors. Today, fewer tests may be needed for siblings, since their cells vary less than an unrelated donor. But to reduce the risks of mismatched types between unrelated donors, more than the basic 6 HLA antigens may be tested. For example, sometimes doctors to try and get a 10 out of 10 match. Certain transplant centers now require high-resolution matching, which looks more deeply into tissue types and allow more specific HLA matching.

There are thousands of different combinations of possible HLA tissue types. This can make it hard to find an exact match. HLA antigens are inherited from both parents. If possible, the search for a donor usually starts with the patients brothers and sisters (siblings), who have the same parents as the patient. The chance that any one sibling would be a perfect match (that is, that you both received the same set of HLA antigens from each of your parents) is 1 out of 4.

If a sibling is not a good match, the search could then move on to relatives who are less likely to be a good match parents, half siblings, and extended family, such as aunts, uncles, or cousins. (Spouses are no more likely to be good matches than other people who are not related.) If no relatives are found to be a close match, the transplant team will widen the search to the general public.

As unlikely as it seems, its possible to find a good match with a stranger. To help with this process, the team will use transplant registries, like those listed here. Registries serve as matchmakers between patients and volunteer donors. They can search for and access millions of possible donors and hundreds of thousands of cord blood units.

Be the Match (formerly the National Marrow Donor Program) Toll-free number: 1-800-MARROW-2 (1-800-627-7692) Website: http://www.bethematch.org

Blood & Marrow Transplant Information Network Toll-free number: 1-888-597-7674 Website: http://www.bmtinfonet.org

The chances of finding an unrelated donor match improve each year, as more volunteers sign up. Today, about half of white people who need a stem cell transplant may find a perfect match among unrelated donors. This drops to about 1 out of 10 people in other ethnic groups, mostly because their HLA types are more diverse and in the past they were less likely to take part in donor registries. Depending on a persons tissue typing, several other international registries also are available. Sometimes the best matches are found in people with a similar racial or ethnic background. Finding an unrelated donor can take months, though cord blood may be a little faster. A single match can require going through millions of records.

Now that transplant centers are more often using high-resolution tests, matching is becoming more complex. Perfect 10 out of 10 matches at that level are much harder to find. But transplant teams are also getting better at figuring out what kinds of mismatches can be tolerated in which particular situations that is, which mismatched antigens are less likely to affect transplant success and survival.

Keep in mind that there are stages to this process there may be several matches that look promising but dont work out as hoped. The team and registry will keep looking for the best possible match for you. If your team finds an adult donor through a transplant registry, the registry will contact the donor to set up the final testing and donation. If your team finds matching cord blood, the registry will have the cord blood sent to your transplant center.

See the rest here:
Types of Stem Cell Transplants for Cancer Treatment ...